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ORIGINAL INVESTIGATION
Lower-extremity amputation as a 
marker for renal and cardiovascular events 
and mortality in patients with long standing 
type 1 diabetes
Kamel Mohammedi1,2*, Louis Potier1,2,3, Narimène Belhatem1,2, Nadia Matallah1,2, Samy Hadjadj4,5,6,7, 
Ronan Roussel1,2,3, Michel Marre1,2,3 and Gilberto Velho1
Abstract 
Background: We evaluated the risks of renal and cardiovascular complications, and mortality associated with lower 
extremity amputation (LEA) in patients with type 1 diabetes.
Methods: We studied two cohorts of people with long standing type 1 diabetes: GENEDIAB (n = 456) and GENESIS 
(n = 611). Subsets of the cohorts (n = 260, n = 544) were followed for 9 and 5 years, respectively. Outcomes were the 
incidence of end stage renal disease (ESRD), myocardial infarction, stroke and mortality during follow-up. Analyses 
were performed in pooled cohorts.
Results: The prevalence of LEA at baseline was 9.3 % (n = 99). A positive history of LEA was associated with the baseline 
prevalence of established (OR 4.50, 95 % CI 2.33–8.91, p < 0.0001) and advanced diabetic nephropathy (OR 5.50, 95 % CI 
2.89–10.78, p < 0.0001), ESRD (OR 2.86, 95 % CI 1.43–5.50, p = 0.004), myocardial infarction (OR 3.25, 95 % CI 1.68–6.15, 
p = 0.0006) and stroke (OR 3.88, 95 % CI 1.67–8.72, p = 0.002, adjusted for sex, age, and cohort membership). A positive 
history of LEA at baseline was associated with the incidence during follow-up of ESRD (HR 2.69, 95 % CI 1.17–6.20, p = 0.02), 
and myocardial infarction (HR 3.53, 95 % CI 1.79–6.97, p = 0.0001). History of LEA was also associated with increased risk for 
all-cause (HR 3.55, 95 % CI 2.05–6.16, p < 0.0001), cardiovascular (HR 3.30, 95 % CI 1.36–8.02, p = 0.008), infectious disease 
(HR 5.18, 95 % CI 1.13–23.84, p = 0.03) and other-cause mortality (HR 2.81, 95 % CI 1.09–7.26, p = 0.03). History of LEA at 
baseline was associated with a 40 % reduction in the duration of survival in the subset of patients who died during follow-
up. Population attributable risk of the history of LEA at baseline for total mortality during follow-up was 0.31.
Conclusions: Patients with LEA have a higher risk of ESRD, myocardial infarction and cardiovascular and non-car-
diovascular mortality. Our results highlight the importance of LEA as a key-predictor for major vascular events and 
premature death in type 1 diabetic patients.
Keywords: Type 1 diabetes, Amputation, Diabetic nephropathy, End stage renal disease, Myocardial infarction, 
Stroke, Mortality
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Background
Lower extremity amputation (LEA) is a severe and fre-
quent complication in patients with diabetes [1, 2]. 
Despite a decline of its incidence in Europe and USA 
in the past decades, LEA remains higher in patients 
with diabetes as compared to those without diabetes 
[3–8]. Moreover, LEA-related mortality is higher in 
diabetic patients than in the general population [9–11]. 
It is a major public health problem worldwide, with a 
significant social and economic burden. LEA requires 
lengthy hospitalizations with frequent and repeated 
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revascularization procedures, supplemented by special-
ized outpatient care [12, 13]. It might result in crippling 
physical and psychological sequelae, with a negative 
impact on the quality of life, leading to social and profes-
sional disabilities [14].
Type 1 diabetes is associated with increased risk of pre-
mature death [15, 16], and this increased mortality risk 
is related mainly to kidney and cardiovascular compli-
cations [15, 17–19]. LEA is also associated with higher 
cardiovascular mortality in people with diabetes [20, 
21]. However, data on LEA and risk of cardiovascular 
and kidney complications, and cause-specific mortality 
in patients with type 1 diabetes are scarce. In the present 
investigation we evaluated LEA-related risk of kidney and 
cardiovascular complications, and cardiovascular and 
non-cardiovascular mortality in two cohorts of patients 
with type 1 diabetes.
Methods
Participants
We studied two multicentre binational (Belgium and 
France) cohorts of people with long standing type 1 dia-
betes designed to study the vascular complications of 
diabetes. GENEDIAB (Génétique de la Néphropathie 
Diabétique) was a prospective cohort conducted, from 
1994 to 2006, in 494 participants with type 1 diabe-
tes selected on the basis of diagnosis of type 1 diabetes 
before the age of 35 years and past or present diagnosis 
of severe diabetic retinopathy [22]. The Genesis France-
Belgium (GENESIS) cohort was a family-based study 
conducted, from 1999 to 2007, in 578 first-degree rela-
tives and 662 probands with type 1 diabetes, selected on 
the basis of a diagnosis of type 1 diabetes before the age 
of 35 years, with initial ketosis and requirement for per-
manent insulin treatment within 1 year of diagnosis and 
past or present diagnosis of diabetic retinopathy [23]. 
In the present investigation, we analysed at baseline 456 
GENEDIAB participants and 611 GENESIS probands for 
whom LEA data was available. Clinical characteristics of 
GENEDIAB and GENESIS participants at baseline are 
shown in the Additional file 1: Table S1.
Follow‑up study
In a prospective observational study, subsets of GEN-
EDIAB (n =  260) and GENESIS (n =  544) participants 
were followed until an end point was reached or until 
February 2007. The subsets were composed of partici-
pants who attended outpatient clinics at least once dur-
ing the follow-up period. Median duration of follow-up 
(and interquartile range) was 10.2 (2.7) and 5.1 (1.5) 
years for GENEDIAB and GENESIS, respectively. Clini-
cal characteristics at baseline of GENESIS participants 
for whom follow-up data were available were similar to 
those of participants without follow-up data (Additional 
file 1: Table S1). GENEDIAB participants for whom fol-
low-up data were available as compared to those without 
follow-up data, were older, had higher eGFR and lower 
prevalence of advanced diabetic nephropathy at baseline. 
Participants of the two cohorts gave written informed 
consent, and study protocols were approved by the eth-
ics committee of Angers University Hospital (Angers, 
France).
Definition of clinical parameters and outcomes
An ad hoc event committee reviewed the case record of 
each patient to validate the diagnosis of renal, retinal, and 
cardiovascular complications, peripheral sensory neu-
ropathy, peripheral artery disease and LEA at baseline 
[22] and later, the incidence of outcomes during follow-
up. LEA was adjudicated as amputation of a lower limb 
(above or below the knee, foot, toes or transmetatarsal) 
resulting from non-traumatic causes. Glomerular fil-
tration rate (eGFR) was estimated by the Modification 
of Diet in Renal Disease (MDRD) formula [24]. Stages 
of diabetic nephropathy were defined as follows: no 
nephropathy, defined as urinary albumin concentra-
tion (UAC) <30 mg/24 h or <20 µg/min or <20 mg/l and 
plasma creatinine  <150  µmol/l in at least 2 of 3 con-
secutive assessments and in the absence of antihyper-
tensive treatment; incipient nephropathy, defined as 
persistent microalbuminuria (UAC  =  30–300  mg/24  h 
or 20–200  µg/min or 20–200  mg/l) and plasma creati-
nine  <150  µmol/l; established nephropathy, defined as 
past or present macroalbuminuria (UAC > 300 mg/24 h 
or  >  200  µg/min or  >  200  mg/l) and plasma creati-
nine  <150  µmol/l; and advanced nephropathy, defined 
as past or present macroalbuminuria and plasma creati-
nine  >150  µmol/l or history of end stage renal disease 
(ESRD), defined as haemodialysis requirement or kidney 
transplantation. Ocular data was obtained by direct fun-
duscopy and/or fluorescein angiography. Diabetic retin-
opathy was staged according to Kohner’s classification as 
non-proliferative, pre-proliferative or proliferative retin-
opathy [25]. Myocardial infarction was diagnosed as the 
occurrence of at least 2 out of 3 of the following criteria: 
constrictive chest pain lasting 20 min or longer, increased 
serum creatinine phosphokinase and/or troponine lev-
els, or typical electrocardiographic changes. Stroke was 
diagnosed as the occurrence of a focal neurologic defi-
cit lasting at least 24 h, associated with evidence of brain 
infarction or haemorrhage by computed tomography or 
magnetic resonance imaging. Incidences of ESRD, myo-
cardial infarction or stroke were defined as new cases 
of these outcomes during follow-up. The cause of death 
was established from hospital records. Missing data 
were completed by a phone interview with the patient’s 
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general practitioner and/or by consulting the death cer-
tificate national registry. All-cause mortality was defined 
as death of any cause occurring during follow-up. Cardi-
ovascular death was defined as death following myocar-
dial infarction, congestive heart failure, arrhythmias and 
stroke. Infectious disease mortality was defined as death 
complicating infectious disease.
Statistical analysis
Results are expressed as mean ± SD except when stated 
otherwise. Differences between groups were assessed 
by analysis of variance (ANOVA), analysis of covariance 
(ANCOVA), and Pearson’s Chi squared test. If the nor-
mality of the distribution was rejected by the Shapiro–
Wilk W test, data were log-transformed for the analyses, 
or Wilcoxon/Kruskal–Wallis test was used. Associa-
tions of a history of LEA with the prevalence of diabetic 
complications at baseline were examined with logistic 
regression analyses. Kaplan–Meier curves were used to 
plot the cumulative incidences of outcomes over time by 
the baseline history of LEA. Cox proportional hazards 
survival regression analyses were used to examine the 
effect of explanatory variables on time-related survival 
(or outcome-free) rates in prospective analyses. Hazard 
ratios (HR) or odds ratios (OR), respectively, with their 
95 % confidence intervals (CI) were computed for a posi-
tive history of LEA at baseline. Competing risk regres-
sion analysis (Fine and Gray model) was performed to 
estimate subhazard ratios of ESRD, myocardial infarc-
tion or stroke assuming death as a competing risk [26]. 
Adjustments for clinical and biological parameters were 
performed by including these parameters as covariates 
in the regression models. Cross-sectional stepwise mul-
tivariable regression analysis of covariates associated 
with the prevalences of the clinical outcomes at the end 
of follow-up were performed as sensitivity analyses. The 
incidence of ESRD, myocardial infarction, stroke or death 
during follow-up could not be ascertained in 62, 16, 30 
and 7 participants, respectively. Those participants were 
not excluded from the study, but only from the analy-
ses of the specific outcome where data were missing. To 
increase statistical power, all analyses were performed in 
GENEDIAB and GENESIS pooled cohorts, with appro-
priate adjustments for covariates to take into account 
cohort differences. p  ≤  0.05 was considered as signifi-
cant. Statistics were performed with the JMP (SAS Insti-
tute Inc., Cary, NC, USA) and Stata (StataCorp, College 
Station, TX, USA) softwares.
Results
Clinical characteristics of participants at baseline
The prevalence of LEA at baseline was 9.3 % (n = 99) in 
GENEDIAB/GENESIS pooled cohorts. Characteristics 
of participants by a history of LEA at baseline are shown 
in Table 1. Individuals with a positive history of LEA as 
compared to other participants were more likely to be 
men, were older at baseline and had a longer duration 
of diabetes. They had higher blood pressure levels, were 
more likely to take antihypertensive medication and to 
have a history of tobacco smoking. Diabetic retinopathy, 
peripheral sensory neuropathy and peripheral artery dis-
ease were more frequent in individuals with LEA.
LEA and kidney and cardiovascular complications 
at baseline
Participants with a positive history of LEA at baseline 
had higher UAC and lower eGFR as compared to par-
ticipants without LEA history. Diabetic nephropathy at 
baseline was more frequent and more severe in partici-
pants with a positive history of LEA (Table  1). Regres-
sion analyses confirmed the associations of a positive 
history of LEA at baseline with the prevalence of estab-
lished and advanced diabetic nephropathy at baseline: 
OR 4.50, 95 % CI 2.33–8.91, p < 0.0001 and OR 5.50, 95 % 
CI 2.89–10.78, p < 0.0001, respectively, in a model with 
minimal covariate adjustment (model 1: sex, age, and 
cohort membership). Associations remained significant 
in a multi-adjusted model taking into account differences 
between groups at baseline (model 2: sex, age, cohort 
membership, duration of diabetes, HbA1c, use of anti-
hypertensive and lipids lowering drugs, and history of 
tobacco smoking): OR 4.49, 95 % CI 2.11–9.79, p < 0.0001 
and OR 6.22, 95 % CI 2.92–13.73, p < 0.0001, for estab-
lished and advanced diabetic nephropathy respectively. 
The prevalence of ESRD at baseline was 7.3 % (n = 78). It 
was higher in participants with a positive history of LEA 
than in other participants (15.2 vs 6.5  %, Pearson’s Chi 
squared test p =  0.002). Regression analyses confirmed 
the association of a positive history of LEA with the base-
line prevalence of ESRD (Additional file 1: Table S2).
The prevalences of previous myocardial infarction and 
stroke at baseline were 5.7 % (n = 61) and 3.3 % (n = 35), 
respectively. Prevalences were significantly higher in 
participants with a positive history of LEA than in other 
participants: 19.2 vs. 4.4  %, respectively, for myocar-
dial infarction (Pearson’s Chi squared test p  <  0.0001), 
and 11.1 vs. 2.5 %, respectively, for stroke (Pearson’s Chi 
squared test p = 0.0001). Regression analyses, with mini-
mal and multi-adjusted models, confirmed the associa-
tion of LEA with the prevalence of previous myocardial 
infarction and stroke at baseline (Additional file 1: Table 
S2).
LEA and clinical outcomes during follow‑up
Cumulative incidences of ESRD, myocardial infarction 
and stroke during follow-up were 7.4 % (n =  55), 6.2 % 
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(n = 49) and 3.4 % (n = 26), respectively. The incidence 
rate of these outcomes was 1.2, 1.0, and 0.5 per 100 per-
son-years, respectively. Characteristics of participants at 
baseline by the incidence of each of the outcomes dur-
ing follow-up are shown in the Additional file 1: Table S3. 
Characteristics by ESRD and myocardial infarction status 
during follow-up were partially published previously [27, 
28]. Briefly, incident cases of ESRD, myocardial infarction 
or stroke during follow-up, compared to participants not 
presenting these outcomes, were older and had a longer 
duration of diabetes at baseline (except for ESRD cases), 
had higher blood pressure, lower eGFR (except for stroke 
cases), higher UAC (except for myocardial infarction 
cases), and were more likely to be taking antihypertensive 
drugs and to present peripheral sensory neuropathy and 
peripheral artery disease. Diabetic nephropathy and dia-
betic retinopathy were more frequent and more severe in 
incident cases of each outcome.
The incidences of ESRD, myocardial infarction and 
stroke during follow-up were higher in participants with 
a positive history of LEA at baseline than in other par-
ticipants (Table  2). Cox proportional hazards survival 
regression analyses confirmed the association of a posi-
tive history of LEA at baseline with the incidence dur-
ing follow-up of ESRD and myocardial infarction both 
in minimal and multi-adjusted models (Table 2). No sig-
nificant association was observed with the incidence of 
stroke. Kaplan–Meier (cumulative incidence) curves for 
ESRD and myocardial infarction during follow-up by the 
history of LEA at baseline are shown in Fig. 1. The asso-
ciation with the incidence of ESRD remained significant 
when we excluded participants with advanced nephropa-
thy at baseline, and when we also excluded participants 
with established nephropathy at baseline (p = 0.003 and 
p = 0.03, respectively, for the multi-adjusted model; data 
not shown). Similarly, the association with the incidence 
of myocardial infarction during follow-up remained sig-
nificant when we excluded from the analysis participants 
with a history of previous myocardial infarction at base-
line, or when we included the history of previous myo-
cardial infarction at baseline as a covariate in the model 
(p  =  0.001 and p  =  0.01, respectively, for the multi-
adjusted model; data not shown).
The associations of a positive history of LEA at base-
line with the incidence of ESRD and myocardial infarc-
tion evaluated with the Cox model might be biased by the 
association of LEA with all-cause mortality (see below) 
if many patients died before achieving the renal or the 
coronary endpoint. Therefore, we performed compet-
ing risk regression analyses to estimate subhazard ratios 
(SHR) for a positive history of LEA as a risk for ESRD or 
myocardial infarction assuming all-cause mortality as a 
competing risk. SHR and HR from the Cox model were 
similar, indicating that death was not a competing risk in 
the association of LEA with ESRD or myocardial infarc-
tion (Table 2, model 3).
Table 1 Characteristics of  participants by  the history 
of lower extremity amputation at baseline
Results expressed as mean ± SD, except urinary albumin concentration 
(UAC) and triglycerides expressed as mean (interquartile range). Statistics 
of quantitative parameters are ANOVA performed with log-transformed 
data or Wilcoxon test (UAC and triglycerides). Antihypertensive drugs: all 
antihypertensive medication classes included. ACE-I angiotensin converting 
enzyme inhibitor, ARB angiotensin receptor blocker. Diabetic nephropathy 
stages: absence, incipient, established, and advanced nephropathy. Diabetic 
retinopathy stages: absent, non-proliferative, pre-proliferative, proliferative
a Data available only in the GENEDIAB cohort: n = 438 for total cholesterol and 
n = 129 for triglycerides
b Current or past history of tobacco smoking
p < 0.05 was significant
History of LEA at baseline p
No Yes
N (%) 968 (90.7) 99 (9.3)
Male sex (%) 51.9 70.7 0.0003
Age (years) 42.6 ± 11.6 51.6 ± 11.2 <0.0001
Age at diabetes onset 
(years)
15.5 ± 9.1 18.3 ± 9.0 0.007
Duration of diabetes 
(years)
27.0 ± 9.3 33.3 ± 9.0 <0.0001
Body mass index (kg/
m2)
24.1 ± 3.5 23.9 ± 3.8 0.40
Systolic BP (mmHg) 134 ± 19 143 ± 20 <0.0001
Diastolic BP (mmHg) 77 ± 11 80 ± 11 0.003
HbA1c (%) and 
(mmol/mol)
8.5 ± 1.5 (70 ± 16) 8.8 ± 2.1 (72 ± 23) 0.31
Plasma creatinine 
(µmol/l)
113 ± 112 166 ± 163 <0.0001
eGFR (ml/
min/1.73 m2)
81 ± 44 60 ± 37 <0.0001
UAC (mg/l) 22 (238) 95 (499) 0.01
Total cholesterola 
(mmol/l)
5.70 ± 1.45 5.67 ± 1.45 0.68
Triglyceridesa 
(mmol/l)
1.13 (0.91) 1.29 (0.5) 0.31
Tobacco smokingb 
(%)
42.3 55.1 0.01
Antihypertensive 
drugs (%)
51.1 73.7 <0.0001
ACE-I or ARB drugs 
(%)
41.3 55.6 0.006
Lipid lowering drugs 
(%)
8.4 11.1 0.35
Diabetic nephropa-
thy stages (%)
46/21/18/15 18/17/30/35 <0.0001
Diabetic retinopathy 
stages (%)
0/27/18/55 0/4/15/81 <0.0001
Peripheral sensory 
neuropathy (%)
46.4 89.7 <0.0001
Peripheral artery 
disease (%)
5.8 93.8 <0.0001
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LEA at baseline and mortality during follow‑up
Death occurred in 72 participants during the follow-up. 
The cumulative incidence of all-cause mortality was 9.0 % 
(incidence rate 1.4 per 100 person-years). It was higher 
in participants with a positive history of LEA at base-
line than in other participants (Table  3). Clinical char-
acteristics of participants at baseline by the incidence 
of all-cause mortality during follow-up were partially 
published previously [27] and are shown in the Addi-
tional file 1: Table S3. Briefly, participants who died dur-
ing follow-up, as compared to those who survived, were 
older at baseline, more frequently of the male sex, had a 
longer duration of diabetes, higher HbA1c, blood pres-
sure, and UAC levels. They had lower eGFR and were 
more likely to have a previous history of tobacco smok-
ing, hypertension and myocardial infarction, and to pre-
sent peripheral sensory neuropathy and peripheral artery 
disease. Diabetic nephropathy and diabetic retinopathy 
were more frequent and more severe in participants who 
died during follow-up. Cox proportional hazards survival 
regression analyses showed a significant association of a 
positive history of LEA at baseline with all cause mortal-
ity during follow-up both in minimal and multi-adjusted 
models (Table  3). Kaplan–Meier (cumulative incidence) 
curve during follow-up by the history of LEA at baseline 
are shown in Fig.  1. A positive history of LEA at base-
line was associated with a 40 % reduction in the duration 
of survival in the subset of participants who died dur-
ing follow-up (2.9 ± 0.7 vs 4.8 ± 0.4 years, mean ± SD, 
p = 0.02, adjusted for sex, age, duration of diabetes and 
cohort membership). Population attributable risk of the 
history of LEA at baseline for total mortality during fol-
low-up was 0.31.
Causes of death during follow-up included cardiovas-
cular complications (38.9 %), infectious diseases (13.9 %), 
cancer (9.7  %), acute metabolic complications (8.3  %), 
kidney complications (2.8  %) and other or undeter-
mined aetiologies (26.4  %). We assessed associations of 
LEA with cause-specific mortality grouped as cardio-
vascular mortality, infectious disease mortality, and all 
other causes of death. For the 3 causes of mortality, the 
incidence during follow-up was higher in participants 
with a positive history of LEA at baseline than in other 
participants (Table  3). Cox proportional hazards sur-
vival regression analyses confirmed the association of 
a positive history of LEA at baseline with the incidence 
of cardiovascular mortality and other causes of mortal-
ity during follow-up in a model with minimal covari-
ate adjustment (Table 3). No significant association was 
observed for infectious disease mortality. However, in a 
multi-adjusted model, associations of LEA were statisti-
cally significant with the incidence of the 3 cause-specific 
mortalities (Table  3). No significant association of LEA 
at baseline with cancer mortality was observed (data not 
shown).
Sensitivity analyses
For sensitivity analyses, we performed cross-sectional 
stepwise multivariable regression analyses with the prev-
alences of diabetic nephropathy, myocardial infarction, 
stroke and all-cause mortality as dependent variables. 
To increase power, we used for each participant the most 
Table 2 Clinical outcomes during follow-up by history of LEA at baseline
Data expressed as number of cases and (%) by line. Hazards ratio (HR) for a positive LEA history at baseline as a risk for ESRD, myocardial infarction and stroke during 
follow-up, computed by Cox proportional hazards survival regressive analysis. Model 1: adjusted for cohort membership, sex and age at baseline. Model 2: adjusted 
for cohort membership, sex, age, duration of diabetes, HbA1c, systolic and diastolic blood pressure and diabetic retinopathy at baseline (risk for ESRD analysis), 
plus UAC and eGFR (risk for myocardial infarction and stroke analyses). Diabetic retinopathy was coded as an ordinal polytomic covariate: non-Proliferative (2), 
pre-Proliferative (3), proliferative (4). Subhazard ratio (SHR) for a positive LEA history at baseline as a risk for ESRD, myocardial infarction and stroke during follow-up, 
assuming death as a competing risk. SHR computed by competing risk regression analysis, adjusted for cohort membership, sex and age at baseline
p < 0.05 is significant
Clinical outcomes during follow‑up
ESRD Myocardial infarction Stroke
No Yes No Yes No Yes
LEA at baseline
 No 644 (93.1 %) 48 (6.9 %) 697 (95.5 %) 33 (4.5 %) 698 (97.1 %) 21 (2.9 %)
 Yes 44 (86.3 %) 7 (13.7 %) 43 (72.9 %) 16 (27.1 %) 51 (91.1) 5 (8.9 %)
HR (95 % CI) model 1 2.69 (1.17–6.20) 3.53 (1.79–6.97) 1.76 (0.60–5.14)
P 0.02 0.0001 0.29
HR (95 % CI) model 2 2.49 (1.02–6.06) 3.21 (1.50– 6.85) 1.28 (0.37–4.43)
P 0.04 0.003 0.69
SHR (95 % CI) model 3 2.41 (1.04–5.87) 3.16 (1.53–6.52) 1.49 (0.46–4.84)
P 0.04 0.002 0.50
Page 6 of 9Mohammedi et al. Cardiovasc Diabetol  (2016) 15:5 
recent set of data available (follow-up, or baseline data if 
follow-up data was not available). Diabetic nephropathy 
was coded as an ordinal polytomic covariate: absence (1), 
incipient (2), established (3) and advanced nephropathy 
(4), and ESRD (5). For diabetic nephropathy analysis, sex, 
age, BMI, systolic and diastolic blood pressure, duration 
of diabetes, diabetic retinopathy stage, HbA1c, history 
of LEA, history of tobacco smoking, use of lipid lower-
ing, antihypertensive and angiotensin converting enzyme 
inhibitor (ACE-I) or angiotensin 2 receptor blocker (ARB) 
drugs, and cohort membership were entered in the model 
as independent covariates. For myocardial infarction and 
stroke analyses, eGFR and UAC were also included as 
independent covariates. For all-cause mortality analysis, 
diabetic nephropathy, myocardial infarction and stroke 
were also included as independent covariates. Thus, use 
of antihypertensive and lipid lowering drugs, history 
of LEA, proliferative diabetic retinopathy, and systolic 
blood pressure remained positively associated, and age 
and BMI inversely associated with diabetic nephropa-
thy (Additional file  1: Table S4), and explained  ~12  % 
of the variation of the trait (cumulated R2). History of 
LEA, age and use of lipid lowering and antihypertensive 
drugs remained positively associated, and eGFR inversely 
associated with the prevalence of myocardial infarction 
(Additional file 1: Table S5), and explained ~18 % of the 
variation of the trait. Systolic blood pressure, duration of 
diabetes, UAC and history of LEA remained positively 
associated with the prevalence of stroke (Additional 
file 1: Table S6), and explained ~14 % of the variation of 
the trait. History of LEA, diabetic nephropathy, myocar-
dial infarction, HbA1c, tobacco smoking, cohort mem-
bership (GENEDIAB), BMI and age remained positively 
associated with all-cause mortality (Additional file  1: 
Table S7), and explained  ~36  % of the variation of the 
trait. History of LEA in these stepwise regression analy-
ses explained 1.4, 9.0, 1.1 and 14.1 % of the variation of 
the four traits, respectively, and provided the highest sin-
gle increase in cumulated R2 in myocardial infarction and 
all-cause mortality regression models.
Discussion
In the present investigation in people with type 1 dia-
betes, a positive history of LEA was associated with 
the prevalence of established and advanced diabetic 
nephropathy, ESRD, myocardial infarction and stroke 
at baseline. LEA at baseline was also associated with 
increased risk during follow-up of ESRD, myocardial 
infarction, all-cause mortality, and specifically, with 
mortality due to cardiovascular and infectious diseases. 
When considering the participants who died during fol-
low-up, a positive history of LEA at baseline was asso-
ciated with a 40 % reduction in the duration of survival. 
Population attributable risk of a positive history of LEA 
at baseline regarding all-cause mortality during follow-
up, that is, the reduction in mortality that would be 
observed in our cohorts in the absence of LEA was 31 %.
Risk factors of lower‑extremity amputation
As in any epidemiological study, these associations may 
be confounded by other factors. For instance, blood glu-
cose control and duration of diabetes are known risk 
factors for LEA [20, 29, 30], but also for cardiovascular 
and renal complications of diabetes. However, the asso-
ciations we have observed with the incidence of ESRD 
and myocardial infarction were independent of relevant 
covariates such as sex, age, duration of diabetes, blood 
Fig. 1 Incidence of outcomes by the history of LEA at baseline. 
Kaplan–Meier curves for the cumulative incidence of end stage renal 
disease (ESRD), myocardial infarction, and all-cause mortality during 
follow-up by the presence (dashed lines) or the absence (solid lines) of 
a history of LEA at baseline
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pressure, HbA1c, UAC, eGFR, antihypertensive and lipid 
lowering treatments, and the current and past history of 
tobacco smoking, suggesting that LEA was an independ-
ent predictor for the clinical outcomes during follow-up. 
Moreover, despite the association of LEA with mortality, 
death was not a competing risk in the association of LEA 
with the incidence of ESRD and myocardial infarction.
Lower‑extremity amputation and risks of kidney 
and cardiovascular complications and mortality
Increased mortality risk associated with LEA has been 
reported previously in people with diabetes [10, 21], but 
to the best of our knowledge, this is the first study that 
investigates the risk associated with a history of LEA on 
the prevalence and the incidence of cardiovascular and 
kidney diseases, and specific causes of mortality in pro-
spective cohorts of type 1 diabetes. Increased risk of mor-
tality in type 1 diabetic individuals with a baseline history 
of LEA as compared to those without LEA was observed 
in the WHO Multinational Study of Vascular Disease in 
Diabetes [20]. The Danish Amputation Register, includ-
ing 1406 type 1 diabetic patients, reported higher rate 
of mortality in patients with LEA as compared to those 
without, particularly during the first year following the 
amputation [31]. A history of LEA was also reported as 
an independent predictor for 5-year mortality in 1444 
patients with type 1 diabetes from the Early Treatment 
Diabetic Retinopathy Study [32]. On the other hand, 
the presence of chronic kidney disease (GFR  <  60  ml/
min) and ESRD were associated with increased rates of 
mortality (46 and 290  %, respectively) in patients with 
diabetes who undergone LEA [33]. LEA was reported in 
1.5–2.5 % of participants in Swedish, German and Amer-
ican surveys of people with type 1 diabetes [6, 34–36]. 
The higher prevalence of LEA in our cohorts at baseline 
(9.3  %) probably reflects the inclusion criteria, which 
included the presence of retinopathy for GENESIS and 
severe (pre-proliferative or proliferative) retinopathy for 
GENEDIAB. Participants from our cohorts were older, 
had a longer duration of diabetes and were more severely 
ill than participants from the other surveys.
Strengths and limitations
LEA is the consequence of acute and chronic podiatric 
complications, including diabetic neuropathy, peripheral 
artery disease, skin microangiopathy with impairment 
of skin blood flow, coagulation disorders and infection 
complications [37–40]. The main limitation of our study 
was that data on specific causes of LEA and on the level 
of amputation (above or below the knee, foot, or toes), 
obtained retrospectively from hospital records, were 
fragmentary and could not be used in the investigation. 
Another limitation was the relatively small number of 
some of the outcomes, potentially reducing the statisti-
cal power to observe associations such as in the case of 
the incidence of stroke or some specific causes of death, 
including kidney disease-related mortality. The main 
strength of our study is the cross-sectional analysis of 
1000 patients with long standing type 1 diabetes from 
two independent cohorts, with a follow-up of 5–9 years 
of more than 800 participants, with detailed renal, cardi-
ovascular and survival outcomes including cause-specific 
mortality data. It is noteworthy that in cross-sectional 
analyses of total prevalence of diabetic nephropathy, 
myocardial infarction, stroke and all-cause mortality, 
LEA remained significantly associated with the all traits, 
including stroke.
Conclusions
LEA reflects widespread micro- and macrovascular dam-
age in people with type 1 diabetes. Patients with LEA 
have a higher risk of ESRD, myocardial infarction and 
Table 3 Mortality during follow-up by history of LEA at baseline
Data expressed as number of cases and (%) by line. Hazards ratio (HR) for a positive LEA history at baseline as a risk for all-cause mortality, cardiovascular, infectious 
disease, and other causes of mortality during follow-up, computed by Cox proportional hazards survival regressive analysis. Model 1: adjusted for cohort membership, 
sex and age at baseline. Model 2: adjusted for cohort membership, sex, age, duration of diabetes, HbA1c, UAC, eGFR, use of antihypertensive and lipids lowering 
drugs, and history of tobacco smoking
p < 0.05 is significant
All‑cause mortality Cardiovascular mortality Infectious disease mortality Other causes of mortality
No Yes No Yes No Yes No Yes
LEA at baseline
 No 691 (93.6 %) 47 (6.4 %) 691 (97.5 %) 18 (2.5 %) 691 (99.0 %) 7 (1.0 %) 691 (96.9 %) 22 (3.1 %)
 Yes 36 (59.0 %) 25 (41.0 %) 36 (78.3 %) 10 (21.7 %) 36 (92.3 %) 3 (7.7 %) 36 (75.0 %) 12 (25.0 %)
HR (95 % CI) model 1 3.55 (2.05–6.16) 4.04 (1.69–9.62) 3.28 (0.73 –14.68) 3.25 (1.44–7.30)
P <0.0001 0.002 0.12 0.004
HR (95 % CI) model 2 2.73 (1.49–5.01) 3.30 (1.36–8.02) 5.18 (1.13–23.84) 2.81 (1.09–7.26)
P 0.001 0.008 0.03 0.03
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premature death from cardiovascular and non-cardio-
vascular causes. Our results confirm the burden of LEA 
in patients with type 1 diabetes beyond podiatric issues, 
and highlight the importance of LEA as a key-predictor 
of severe outcomes.
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